概述
This document updates and expands the initial Infectious Diseases Society of America （IDSA） Fever and Neutropenia Guideline that was published in 1997 and first updated in 2002。 It is intended as a guide for the use of antimicrobial agents in managing patients with cancer who experience chemotherapy-induced fever and neutropenia。
Recent advances in antimicrobial drug development and technology， clinical trial results， and extensive clinical experience have informed the approaches and recommendations herein。 Because the previous iteration of this guideline in 2002， we have a developed a clearer definition of which populations of patients with cancer may benefit most from antibiotic， antifungal， and antiviral prophylaxis。 Furthermore， categorizing neutropenic patients as being at high risk or low risk for infection according to presenting signs and symptoms， underlying cancer， type of therapy， and medical comorbidities has become essential to the treatment algorithm。 Risk stratification is a recommended starting point for managing patients with fever and neutropenia。 In addition， earlier detection of invasive fungal infections has led to debate regarding optimal use of empirical or preemptive antifungal therapy， although algorithms are still evolving。
